Sensus Healthcare (SRTS) to Release Earnings on Wednesday

Sensus Healthcare (NASDAQ:SRTS) is projected to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Sensus Healthcare to post earnings of ($0.09) per share and revenue of $8.3450 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 7:00 AM ET.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 5.67% and a negative net margin of 8.44%.The company had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.31 million. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sensus Healthcare Stock Down 0.4%

Shares of NASDAQ SRTS opened at $5.11 on Tuesday. The stock’s 50 day moving average price is $4.33 and its 200-day moving average price is $3.92. The company has a market capitalization of $83.91 million, a PE ratio of -26.89 and a beta of 1.21. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $9.08.

Wall Street Analysts Forecast Growth

SRTS has been the topic of several research reports. Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Sensus Healthcare has an average rating of “Hold” and a consensus target price of $8.00.

Insider Buying and Selling at Sensus Healthcare

In other Sensus Healthcare news, CEO Joseph C. Sardano bought 25,000 shares of Sensus Healthcare stock in a transaction on Tuesday, November 18th. The stock was acquired at an average price of $4.03 per share, with a total value of $100,750.00. Following the acquisition, the chief executive officer owned 1,200,293 shares in the company, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Sachetta purchased 7,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were bought at an average cost of $3.93 per share, for a total transaction of $27,510.00. Following the acquisition, the director owned 140,113 shares in the company, valued at approximately $550,644.09. The trade was a 5.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 36,500 shares of company stock worth $147,570. 8.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Sensus Healthcare

An institutional investor recently raised its position in Sensus Healthcare stock. Geode Capital Management LLC raised its holdings in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 2.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 153,917 shares of the company’s stock after acquiring an additional 3,766 shares during the quarter. Geode Capital Management LLC owned approximately 0.94% of Sensus Healthcare worth $730,000 as of its most recent SEC filing. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.